Related references
Note: Only part of the references are listed.Immunological challenges for peptide-based immunotherapy in glioblastoma
Malte Mohme et al.
CANCER TREATMENT REVIEWS (2014)
EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss
John H. Sampson et al.
CLINICAL CANCER RESEARCH (2014)
Immunotherapy for Brain Cancer: Recent Progress and Future Promise
Christopher M. Jackson et al.
CLINICAL CANCER RESEARCH (2014)
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Scott D. Brown et al.
GENOME RESEARCH (2014)
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme
Adam M. Swartz et al.
IMMUNOTHERAPY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Mahesh Yadav et al.
NATURE (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
Zineb Belcaid et al.
PLOS ONE (2014)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson et al.
SCIENCE (2014)
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel et al.
SCIENCE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Hematogenous dissemination of glioblastoma multiforme
Carolin Mueller et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression
James P. Sullivan et al.
CANCER DISCOVERY (2014)
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
Patrick J. Killela et al.
ONCOTARGET (2014)
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens
Harm Westdorp et al.
FRONTIERS IN IMMUNOLOGY (2014)
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
Marit M. van Buuren et al.
ONCOIMMUNOLOGY (2014)
Exomics and immunogenics Bridging mutational load and immune checkpoints efficacy
Stephane Champiat et al.
ONCOIMMUNOLOGY (2014)
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
Evan J. Lipson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
TERT promoter mutations in primary and secondary glioblastomas
Naosuke Nonoguchi et al.
ACTA NEUROPATHOLOGICA (2013)
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Surasak Phuphanich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The repertoire of human tumor-associated epitopes - identification and selection of antigens and their application in clinical trials
Sebastian P. Haen et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Jing Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients
Mohamad A. Salkeni et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
The integrated landscape of driver genomic alterations in glioblastoma
Veronique Frattini et al.
NATURE GENETICS (2013)
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Shota Tanaka et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Immunoediting and antigen loss: overcoming the Achilles heel of immunotherapy with antigen non-specific therapies
Arta Monir Monjazeb et al.
FRONTIERS IN ONCOLOGY (2013)
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations
Xiao-Yang Liu et al.
ACTA NEUROPATHOLOGICA (2012)
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
Valerie Dutoit et al.
BRAIN (2012)
Exploiting the Mutanome for Tumor Vaccination
John C. Castle et al.
CANCER RESEARCH (2012)
IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2012)
The role of STAT3 activation in modulating the immune microenvironment of GBM
Alfred P. See et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons J. M. van den Eertwegh et al.
LANCET ONCOLOGY (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Detection of IDH1 mutation in the plasma of patients with glioma
Blandine Boisselier et al.
NEUROLOGY (2012)
Cancer Immunoediting in Malignant Glioma
Gavin P. Dunn et al.
NEUROSURGERY (2012)
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Yuchen Jiao et al.
ONCOTARGET (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
Camilo E. Fadul et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?
Amy B. Heimberger et al.
NEURO-ONCOLOGY (2011)
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
John H. Sampson et al.
NEURO-ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Chetan Bettegowda et al.
SCIENCE (2011)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Emerging Toxicity Profiles of Anti-CTLA-4 Antibodies Across Clinical Indications
Anna Maria Di Giacomo et al.
SEMINARS IN ONCOLOGY (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
John H. Sampson et al.
MOLECULAR CANCER THERAPEUTICS (2009)
P16 PROMOTER METHYLATION IN THE SERUM AS A BASIS FOR THE MOLECULAR DIAGNOSIS OF GLIOMAS
Toshihiko Wakabayashi et al.
NEUROSURGERY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao et al.
SCIENCE (2009)
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway
Nuria de la Iglesia et al.
GENES & DEVELOPMENT (2008)
Immunotherapy of malignant brain tumors
Duane A. Mitchell et al.
IMMUNOLOGICAL REVIEWS (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
Amy B. Heimberger et al.
NEURO-ONCOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?
Matthias Mehling et al.
ACTA NEUROPATHOLOGICA (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas
Richard C. E. Anderson et al.
NEUROSURGERY (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses
S. Farzana Hussain et al.
NEURO-ONCOLOGY (2006)
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
PE Fecci et al.
CANCER RESEARCH (2006)
Methylated tumor-specific DNA as a plasma biomarker in patients with glioma
KD Weaver et al.
CANCER INVESTIGATION (2006)
Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors
A Facoetti et al.
CLINICAL CANCER RESEARCH (2005)
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
LM Liau et al.
CLINICAL CANCER RESEARCH (2005)
Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma
RO Dillman et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity
G Lammering et al.
CLINICAL CANCER RESEARCH (2004)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
JH Sampson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters β-tubulin isotype expression
RB Montgomery et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
